4:28 PM ET
Earnings Call
▶ Call
Surrozen Earnings Call: Key Takeaways
Surrozen is transitioning to a clinical-stage company with a dual-mechanism approach for retinal diseases, backed by a $95 million financing tranche triggered by IND opening.